Full Text View
Tabular View
No Study Results Posted
Related Studies
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
This study has been completed.
Study NCT00572572   Information provided by Hoosier Oncology Group

First Received on December 11, 2007.   Last Updated on November 19, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Germ Cell Tumors
Additional conditions recognized in this trial
Neoplasms, Germ Cell and Embryonal
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Aprepitant
Placebo
Additional drug interventions recognized in this trial
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Hoosier Oncology Group
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services